Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer
- 14 February 2017
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (4) , 985-991
Abstract
Purpose: To determine whether MRI/ultrasound (MRI/US) fusion biopsy facilitates longitudinal resampling of the same clonal focus of prostate cancer and to determine whether high-grade cancers can evolve from low-grade clones. Experimental Design: All men on active surveillance who underwent tracking MRI/US fusion biopsy of Gleason 6 prostate cancer, on at least two distinct occasions, between 2012 and 2014 were enrolled. MRI/US fusion was used to track and resample specific cancer foci. IHC for ERG and targeted RNA/DNA next-generation sequencing (NGS) were performed on formalin-fixed paraffin-embedded prostate biopsy specimens to assess clonality. Results: Thirty-one men with median age and PSA of 65 years and 4.6 ng/mL, respectively, were analyzed. The median sampling interval was 12 months (range, 5–35). Of the 26 evaluable men, ERG IHC concordance was found between initial and repeat biopsies in 25 (96%), indicating resampling of the same clonal focus over time. Targeted NGS supported ERG IHC results and identified unique and shared driving mutations, such as IDH1 and SPOP, in paired specimens. Of the nine men (34.6%) who were found to have Gleason ≥7 on repeat biopsy, all displayed temporal ERG concordance. Prioritized genetic alterations were detected in 50% (13/26) of paired samples. Oncogenic mutations were detected in 22% (2/9) of Gleason 6 cancers prior to progression and 44% (4/9) of Gleason ≥7 cancers when progression occurred. Conclusions: Precise tracking of prostate cancer foci via MRI/US fusion biopsy allowed subsequent resampling of the same clonal focus of cancer over time. Further research is needed to clarify the grade progression potential of Gleason 6 prostate cancer. Clin Cancer Res; 23(4); 985–91. ©2016 AACR.Keywords
All Related Versions
This publication has 40 references indexed in Scilit:
- Tracking the clonal origin of lethal prostate cancerJournal of Clinical Investigation, 2013
- Gleason Grade Progression Is UncommonCancer Research, 2013
- Correlation of UrineTMPRSS2:ERGandPCA3to ERG+ and Total Prostate Cancer BurdenAmerican Journal of Clinical Pathology, 2012
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancerNature Genetics, 2012
- Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy Improves Cancer Detection Following Transrectal Ultrasound Biopsy and Correlates With Multiparametric Magnetic Resonance ImagingJournal of Urology, 2011
- Clinical application of a 3D ultrasound-guided prostate biopsy systemUrologic Oncology: Seminars and Original Investigations, 2011
- ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratificationProstate Cancer and Prostatic Diseases, 2010
- Mechanically assisted 3D ultrasound guided prostate biopsy systemMedical Physics, 2008
- Guideline for the Management of Clinically Localized Prostate Cancer: 2007 UpdateJournal of Urology, 2007
- DEDIFFERENTIATION OF PROSTATE CANCER GRADE WITH TIME IN MEN FOLLOWED EXPECTANTLY FOR STAGE T1C DISEASEJournal of Urology, 2001